Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill hopes to fight advanced cancers when other treatments fail

NCT ID NCT07163325

Disease control Sponsor: Epics Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental oral drug called EP102 in people with advanced solid tumors who have no other treatment options. The main goals are to find the safest dose and understand side effects. About 48 participants with specific cancer types will take the drug by mouth, and researchers will monitor how the body processes it and whether it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have a histological diagnosis of locally advanced or metastatic malignant solid tumors of one of the following cancer types: * ovarian cancer * cervical cancer * endometrial cancer * testicular cancer * cholangiocarcinoma * thyroid cancer * parathyroid cancer * adrenal cancer * pancreatic cancer * non-small-cell lung cancer (NSCLC) * head-and neck cancer * renal cell cancer * urethral cancer * bladder cancer * colorectal cancer * gastric cancer * esophageal cancer * triple-negative breast cancer * thymoma * soft tissue sarcoma * Participants must have failed (i.e. progressed on, or been intolerant to standard treatment), or no standard treatment must exist, or they must have refused standard treatment. All participants must have received at least one prior line of systemic therapy. * Participants must have at least one measurable lesion per RECIST v1.1. * Participant must have a life expectancy of at least 12 weeks. Exclusion Criteria: * Participants with an active severe infection or unexplained fever \> 38.5°C during screening or on the first day of study drug administration are excluded. However, at the Investigator's discretion, participants with tumor-related fever may be enrolled. * Participants with known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg) positive in serum), or active hepatitis C virus (HCV) infection (HCV RNA positive in serum). * Participants with known dysphagia, short-bowel syndrome, gastroparesis, or any condition that may impair the ingestion or gastrointestinal absorption of orally administered drugs. * Pregnant or breastfeeding participants. * Participants who have received IMP or devices in other clinical trials within four weeks before the first dose. * Participants with prior exposure to selective METTL3 inhibitor therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor (phase 1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor (phase 1)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    11 sites in 4 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Cliniques universitaires Saint-Luc

    RECRUITING

    Brussels, 1200, Belgium

    Contact Email: •••••@•••••

  • Hospital Universitari Vall d'Hebron - Vall d'Hebron Institute of Oncology

    RECRUITING

    Barcelona, 8035, Spain

    Contact Email: •••••@•••••

  • Hospital Universitario de Santiago de Compostela

    RECRUITING

    Santiago de Compostela, 15706, Spain

    Contact Email: •••••@•••••

  • Institut Jules Bordet

    RECRUITING

    Brussels, 1070, Belgium

    Contact Email: •••••@•••••

  • Leuven Cancer Institute (LKI)

    RECRUITING

    Leuven, 3000, Belgium

    Contact Email: •••••@•••••

  • Masaryk Memorial Cancer Institute

    RECRUITING

    Brno, 656 53, Czechia

    Contact Email: •••••@•••••

  • Netherlands Cancer Institute (NKI)

    RECRUITING

    Amsterdam, 1066 CX, Netherlands

    Contact Email: •••••@•••••

  • Olomouc University Hospital

    RECRUITING

    Olomouc, 77900, Czechia

    Contact Email: •••••@•••••

  • START Madrid - CIOCC

    RECRUITING

    Madrid, 28050, Spain

    Contact Email: •••••@•••••

  • Universitair Ziekenhuis Gent (UZ Gent) - Drug Research Unit Gent (DRUG)

    RECRUITING

    Ghent, 9000, Belgium

    Contact Email: •••••@•••••

  • University Medical Center Groningen, University of Groningen Department of Medical Oncology

    RECRUITING

    Groningen, 9713 GZ, Netherlands

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.